“Real-World” Breo Study: A Q&A With GSK’s David Leather

GlaxoSmithKline initiated an innovative clinical trial called the Salford Lung Study in 2012 to evaluate with as little intervention from the clinical trial team as possible how its once-daily ICS/LABA Breo Ellipta impacts health outcomes versus existing treatments, and the company is relying heavily on electronic health records to track patients’ outcomes and health care utilization. David Leather, MD, global medical affairs leader for GSK’s respiratory franchise, is heading the trial and talks about the trial design, challenges, and why the company launched the study in the first place.